Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BFRI alert in real time by email
SC 13G/A 1 rosalind_bfri_13ga3_nov2.htm Schedule 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 3)

Under the Securities Exchange Act of 1934

BIOFRONTERA INC.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

09077D209

(CUSIP Number)

October 31, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨  Rule 13d-1(b)
x  Rule 13d-1(c)
¨  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 2 of 9 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Advisors, Inc.

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER  
 
0

 

6.

 

SHARED VOTING POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9%1

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

CO

 

 


1 This percentage is calculated based upon 6,218,932 shares of common stock outstanding of the Issuer as of August 12, 2024, which includes 5,543,518 shares as disclosed by the Issuer on Form 10-Q filed on August 14, 2024, and an additional 675,414 converted shares from the conversion of Series B-2 Preferred Stock. However, as more fully described in Item 3, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


 

NYC#: 139632.2


 

 

 

 

 

 

 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 3 of 9 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Steven Salamon

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 

426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9%

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

IN

 

 

 

 

 

 

 


 

NYC#: 139632.2


 

 

CUSIP No. 09077D209

 

13G/A

 

Page 4 of 9 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Gilad Aharon

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
ONTARIO, CANADA

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

7.

 

SOLE DISPOSITIVE POWER
 

 

8.

 

SHARED DISPOSITIVE POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9%

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

IN

 

 

 

 

 

 

 


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 5 of 9 Pages

 

 

 

 

 

 

 

 

 

 

1.

 

NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Rosalind Master Fund L.P.

 

 

2.

 

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    ¨

 

 

3.

 

SEC USE ONLY
 

 

 

4.

 

CITIZENSHIP OR PLACE OF ORGANIZATION
 
CAYMAN ISLANDS

 

 

 

 

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

 

5.

 

SOLE VOTING POWER
 
0

 

6.

 

SHARED VOTING POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

7.

 

SOLE DISPOSITIVE POWER
 
0

 

8.

 

SHARED DISPOSITIVE POWER
 
426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

 

 

9.

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

426,002 shares of Common Stock

7,196,776 shares of Common Stock issuable upon exercise of preferred shares

 

 

 

10.

 

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)  ¨

 

 

11.

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9%

 

 

12.

 

TYPE OF REPORTING PERSON (see instructions)

PN

 

 

 

 

 

 

 

 

 

 

 

 


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 6 of 9 Pages

 

 

 

 

 

Item 1.

 

(a)

Name of Issuer: BIOFRONTERA INC.

 

 

 

 

(b)

Address of Issuer’s Principal Executive Offices
120 Presidential Way, Suite 330, Woburn, Massachusetts.

 

 

 

Item 2.

 

(a)

Name of Person Filing

Rosalind Advisors, Inc. (“Advisor” to RMF)

Rosalind Master Fund L.P. (“RMF”)

Steven Salamon (“President”)

Steven Salamon is the portfolio manager of the Advisor which advises RMF.

Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

 

 

 

 

 

(b)

Address of the Principal Office or, if none, residence
Rosalind Advisors, Inc.

15 Wellesley Street West

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

Rosalind Master Fund L.P.

P.O. Box 309

Ugland House, Grand Cayman

KY1-1104, Cayman Islands

 

Steven Salamon

15 Wellesley Street West

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

Gilad Aharon

15 Wellesley Street West

Suite 326

Toronto, Ontario

M4Y 0G7 Canada

 

 

 

 

(c)

The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises Rosalind Master Fund L.P.

 

 

 

 

(d)

No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

 

 

 

(e)

No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

 

 

 

(f)

Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 7 of 9 Pages

 

 

 

 

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

¨

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

 

 

 

 

(b)

¨

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

 

 

 

 

(c)

¨

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

 

 

 

 

(d)

¨

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

 

 

 

 

(e)

¨

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

 

 

 

 

(f)

¨

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

 

 

 

 

(g)

¨

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

 

 

 

 

(h)

¨

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

 

 

 

 

(i)

¨

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

 

 

 

 

(j)

¨

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

 

 

 

Item 4.  Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

 

 

 

 

 

(a)

 

Amount beneficially owned:  

 

The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 6,218,932 Ordinary shares of the Issuer’s common stock outstanding as of August 12, 2024, which includes 5,543,518 shares as reported by the Issuer on 10-Q filed on August 14, 2024, and an additional 675,414 converted shares from the conversion of Series B-2 Preferred Stock.

Rosalind Master Fund L.P. is the record owner of 426,002 shares of Common Stock, 2,602,488 shares of common stock issuable upon conversion of B-2 preferred shares and 4,594,288 shares of Common Stock issuable upon conversion of B-3 preferred shares.

Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.  

 

 

 

 

 

 

(b)

 

Percent of class:  

Rosalind Advisors, Inc. –  6.9%

Rosalind Master Fund L.P. –  6.9%

Steven Salamon –  6.9%

Gilad Aharon –  6.9%

 

 

 

 

 


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 8 of 9 Pages

 

 

 

 

 

 

(c)

 

Number of shares as to which the person has:  

 

 

 

(i)

Shared power to vote or to direct the vote  

Rosalind Advisors, Inc. –  426,002

Rosalind Master Fund L.P. –  426,002

Steven Salamon – 426,002

Gilad Aharon - 426,002

 

 

 

 

 

 

 

 

(ii)

Sole power to dispose or to direct the disposition of  – 0

 

 

 

 

 

 

 

 

(iii)

Shared power to dispose or to direct the disposition of  

Rosalind Advisors, Inc. –  426,002

Rosalind Master Fund L.P. –  426,002

Steven Salamon –  426,002

Gilad Aharon - 426,002

 

 

 

 

 

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5.  Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Instruction. Dissolution of a group requires a response to this item.

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

Item 7 – 9.  Not Applicable


 

NYC#: 139632.2


 

 

 

 

 

 

CUSIP No. 09077D209

 

13G/A

 

Page 9 of 9 Pages

 

 

 

 

 

Item 10.  Certification.

 

 

 

 

 

 

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

11/5/2024

Date

 

 

Signature

 

Steven Salamon/President Rosalind Advisors, Inc.

Name/Title

 

 

Exhibit A

Joint Filing Agreement

 

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. is filed jointly, on behalf of each of them.

 

 

Rosalind Advisors, Inc.

By: _____________________________

Name: Steven Salamon

Title: President

 

Rosalind Master Fund L.P.

By: _____________________________

Name: Mike McDonald

Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

 

By: _____________________________

Name: Steven Salamon


 

NYC#: 139632.2

Get the next $BFRI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BFRI

DatePrice TargetRatingAnalyst
12/15/2021$11.00Buy
Benchmark
11/24/2021$20.00Buy
Roth Capital
More analyst ratings

$BFRI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

    Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $34.1 million in 2023 with Q4 2024 growing 18.5% over Q4 2023. The growth was primarily driven by increases in Ameluz® sales volume and unit price, and the successful launch of our RhodoLED® XL Lam

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

    First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of mild to moderate actinic keratoses (AKs) on the

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

    WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information DateFriday, March 21, 2025Time10:00 AM Eastern TimeDial In Numbers1-877-877-1275 (U.S.)1-412-858-5202 (international)WebcastFourth Quarter and FY 2024 Financial Results a

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BFRI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BFRI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BFRI
SEC Filings

See more

$BFRI
Leadership Updates

Live Leadership Updates

See more
  • Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

    WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

    WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. Announces Resignation of CEO

    Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BFRI
Financials

Live finance-specific insights

See more
  • Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

    Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $34.1 million in 2023 with Q4 2024 growing 18.5% over Q4 2023. The growth was primarily driven by increases in Ameluz® sales volume and unit price, and the successful launch of our RhodoLED® XL Lam

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

    WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information DateFriday, March 21, 2025Time10:00 AM Eastern TimeDial In Numbers1-877-877-1275 (U.S.)1-412-858-5202 (international)WebcastFourth Quarter and FY 2024 Financial Results a

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

    WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the "Note") with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company's assets. The principal amount of the Note in whole or in part is convertible into common shares at the holder's discretion at a fixed conversion price of $0.78. Alternatively, the entire amount of the no

    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BFRI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more